Reference number(s) 1914-A, 1915-A

SPECIALTY GUIDELINE MANAGEMENT

FOLLISTIM AQ (follitropin beta injection) GONAL-F (follitropin alfa injection)

*Hereafter, follitropin will be used to describe all products

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications

- A. Follistim AQ is indicated for:
 - 1. Induction of ovulation and pregnancy in anovulatory infertile women in whom the cause of infertility is functional and not due to primary ovarian failure.
 - 2. Pregnancy in normal ovulatory women undergoing controlled ovarian stimulation as part of an in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
 - 3. Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism (HH) in whom the cause of infertility is not due to primary testicular failure.

B. Gonal-f is indicated for:

- 1. Induction of ovulation and pregnancy in oligio-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure.
- 2. Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle.
- 3. Induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

All other indications are considered experimental/investigational and not medically necessary.

II. MEDICAL BENEFIT ALIGNMENT

Specialty Guideline Management coverage review will be bypassed for drug(s) being requested for a procedure that has been approved under a member's medical benefit plan. Such members will be exempt from the requirements in Sections IV. A medical authorization number and confirmation of the approved procedure(s) will be required.

NOTE: Some plans may opt-out of medical benefit alignment. Members receiving coverage under such plans must meet the requirements in Sections IV.

III. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review for hypogonadotropic hypogonadism: testosterone, follicular stimulating hormone (FSH), and luteinizing hormone (LH) levels.

Follitropins 1914-A, 1915-A SGM P2024.docx

© 2024 Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This page contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



IV. CRITERIA FOR INITIAL APPROVAL

A. Follicle stimulation

Authorization of 12 months may be granted for members undergoing ovulation induction or assisted reproductive technology (ART) who meet any of the following criteria:

- 1. Member has completed three or more previous cycles of clomiphene or letrozole.
- 2. Member has a risk factor for poor ovarian response to clomiphene or letrozole.
- 3. Member has a contraindication or exclusion to clomiphene or letrozole.
- 4. Member is 37 years of age or older.

B. Hypogonadotropic hypogonadism

Authorization of 12 months may be granted for treatment of hypogonadotropic hypogonadism in members who meet both of the following criteria:


- 1. Member has low pretreatment testosterone levels.
- 2. Member has low or low to normal follicle stimulating hormone (FSH) or luteinizing hormone (LH)

V. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

VI. REFERENCES

- 1. Follistim AQ Cartridge [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; March 2023.
- 2. Gonal-f Multi-Dose [package insert]. Rockland, MA: EMD Serono, Inc.; December 2023.
- 3. Gonal-f RFF [package insert]. Rockland, MA: EMD Serono, Inc.; November 2023.
- 4. Gonal-f RFF Redi-ject [package insert]. Rockland, MA: EMD Serono, Inc.; May 2024.
- 5. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com/ Accessed: May 14, 2024.
- 6. Practice Committee of the American Society for Reproductive Medicine. Evidence-based treatments for couples with unexplained infertility: a guideline. Fertil & Steril. 2020. 113(2):305-322.
- 7. American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 Update. Endocr Pract. 2002:8:439-456.



manufacturers that are not affiliated with CVS Caremark.

© 2024 Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written